M. Dougados, D. Baeten, and . Spondyloarthritis, Lancet Lond Engl. 18 juin, vol.377, issue.9783, pp.2127-2164, 2011.

S. Carette, D. Graham, H. Little, J. Rubenstein, and P. Rosen, The natural disease course of ankylosing spondylitis, Arthritis Rheum. févr, vol.26, issue.2, pp.186-90, 1983.

A. Wanders, R. Landewé, M. Dougados, H. Mielants, S. Van-der-linden et al., Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: can assessment of spinal mobility be a proxy for radiographic evaluation?, Ann Rheum Dis. juill, vol.64, issue.7, pp.988-94, 2005.

A. Kerschbaumer, D. Baker, J. S. Smolen, and D. Aletaha, The effects of structural damage on functional disability in psoriatic arthritis, Ann Rheum Dis. déc, vol.76, issue.12, pp.2038-2083, 2017.

J. W. Liew, S. Ramiro, and L. S. Gensler, Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis, Best Pract Res Clin Rheumatol. juin, vol.32, issue.3, pp.369-89, 2018.

N. Yeremenko, J. E. Paramarta, and D. Baeten, The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis, Curr Opin Rheumatol. juill, vol.26, issue.4, pp.361-70, 2014.

P. R. Burton, D. G. Clayton, L. R. Cardon, and N. Craddock, Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants, Wellcome Trust Case Control Consortium, Australo-Anglo-American Spondylitis Consortium (TASC), vol.39, pp.1329-1366, 2007.

M. L. Delay, M. J. Turner, E. I. Klenk, J. A. Smith, D. P. Sowders et al., HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats, Arthritis Rheum. sept, vol.60, issue.9, pp.2633-2676, 2009.

S. Glatigny, I. Fert, M. A. Blaton, R. J. Lories, L. M. Araujo et al., Proinflammatory Th17 cells are expanded and induced by dendritic cells in spondylarthritis-prone HLA-B27-transgenic rats, Arthritis Rheum. janv, vol.64, issue.1, pp.110-130, 2012.

C. Jandus, G. Bioley, J. Rivals, J. Dudler, D. Speiser et al., Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides, Arthritis Rheum. août, vol.58, issue.8, pp.2307-2324, 2008.

H. Appel, R. Maier, P. Wu, R. Scheer, A. Hempfing et al., Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response, Arthritis Res Ther. 20 juin, vol.13, issue.3, p.95, 2011.

J. P. Sherlock, B. Joyce-shaikh, S. P. Turner, C. Chao, M. Sathe et al., IL-23 induces spondyloarthropathy by acting on ROR-?t+ CD3+CD4-CD8-entheseal resident T cells, Nat Med. 1 juill, vol.18, issue.7, pp.1069-76, 2012.

I. B. Mcinnes, A. Kavanaugh, A. B. Gottlieb, L. Puig, P. Rahman et al., Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial, Lancet Lond Engl. 31 août, vol.382, issue.9894, pp.780-789, 2013.

C. Ritchlin, P. Rahman, A. Kavanaugh, I. B. Mcinnes, L. Puig et al., Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial, Ann Rheum Dis. juin, vol.73, issue.6, pp.990-999, 2014.

A. Kavanaugh, C. Ritchlin, P. Rahman, L. Puig, A. B. Gottlieb et al., Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials, Ann Rheum Dis. juin, vol.73, issue.6, pp.1000-1006, 2014.

A. Kavanaugh, L. Puig, A. B. Gottlieb, C. Ritchlin, S. Li et al., Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial, Arthritis Care Res. déc, vol.67, issue.12, pp.1739-1788, 2015.

P. J. Mease, I. B. Mcinnes, B. Kirkham, A. Kavanaugh, P. Rahman et al., Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis, N Engl J Med, vol.373, issue.14, pp.1329-1368, 2015.

I. B. Mcinnes, P. J. Mease, B. Kirkham, A. Kavanaugh, C. T. Ritchlin et al., Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Lond Engl, vol.386, issue.9999, pp.1137-1183, 2015.

D. Baeten, J. Sieper, J. Braun, X. Baraliakos, M. Dougados et al., Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis, N Engl J Med. 24 déc, vol.373, issue.26, pp.2534-2582, 2015.

K. Pavelka, A. Kivitz, E. Dokoupilova, R. Blanco, M. Maradiaga et al., Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3, Arthritis Res Ther, vol.22, issue.1, p.285, 2017.

F. Iannone, L. Santo, R. Bucci, A. Semeraro, G. Carlino et al., Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE), Clin Rheumatol. mars, vol.37, issue.3, pp.667-75, 2018.

M. S. Chimenti, A. Ortolan, M. Lorenzin, P. Triggianese, M. Talamonti et al., Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study, Clin Rheumatol. févr, vol.37, issue.2, pp.397-405, 2018.

M. Napolitano, L. Costa, F. Caso, M. Megna, R. Scarpa et al., Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study, Clin Rheumatol. juill, vol.36, issue.7, pp.1589-93, 2017.

R. Queiro, A. Brandy, M. C. Rosado, A. Lorenzo, P. Coto et al., Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis: A Real-World Evidence Study With Ustekinumab, J Clin Rheumatol Pract Rep Rheum Musculoskelet Dis. oct, vol.24, issue.7, pp.381-385, 2018.

M. Michel, Z. Reguiai, M. Fauconier, P. Brochot, J. Eschard et al.,

, Therapie. juin, vol.71, issue.3, pp.281-287, 2016.

M. Almirall, J. Rodriguez, L. Mateo, J. M. Carrascosa, J. Notario et al., Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice, Clin Rheumatol. févr, vol.36, issue.2, pp.439-482, 2017.

J. A. Singh, G. Guyatt, A. Ogdie, D. D. Gladman, C. Deal et al., American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis, Arthritis Care Res. janv, vol.71, issue.1, pp.2-29, 2018.

L. Gossec, J. S. Smolen, R. S. De-wit, M. Cutolo, M. Dougados et al., European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update, Ann Rheum Dis. mars, vol.75, issue.3, pp.499-510, 2016.

L. C. Coates, A. Kavanaugh, P. J. Mease, E. R. Soriano, L. Acosta-felquer et al., Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis: GRAPPA TREATMENT RECOMMENDATIONS FOR PsA, Arthritis Rheumatol. mars, 2016.

M. M. Ward, A. Deodhar, L. S. Gensler, M. Dubreuil, D. Yu et al., Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis, Arthritis Care Res, 2019.

D. Sur,

D. Van-der-heijde, R. S. Landewé, R. Baraliakos, X. Van-den-bosch, F. Sepriano et al., 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis, Ann Rheum Dis. juin, vol.76, issue.6, pp.978-91, 2017.

D. Wendling, C. Lukas, C. Prati, P. Claudepierre, L. Gossec et al., 2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis, Joint Bone Spine. mai, vol.85, issue.3, pp.275-84, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01794588

. Jg and . Letarouilly,

B. Flachaire,

C. Labadie,

J. Sellam,

P. Richette,

P. Dieude,

P. ,

. Claudepierre,

E. Houvenagel,

C. Nguyen,

. Mh and . Guyot,

N. Segaud,

F. Maury,

L. Marguerie,

X. Deprez,

J. H. Salmon,

G. Baudens,

E. Gervais, , vol.17

I. Chary-valckenaere,

D. Loeuille,

C. Richez,

T. Pham,

R. M. Flipo,

S. A. Rheumatology, A. Hospital, and P. ;. Rheumatology, ) Rheumatology, Henri Mondor Hospital, Rheumatology, Bichat Hospital, issue.5

H. Rheumatology and . Bethune, Rheumatology, issue.10

J. A. Walsh, 14) Rheumatology, Hospital of Valenciennes, Valenciennes, Private Practice, vol.54, issue.12, pp.623-631, 2018.

B. Flachaire,

. Jg and . Letarouilly,

C. Labadie,

N. Cohen,

V. Pradel,

J. Sellam,

P. ,

. Richette,

P. Dieude,

P. Claudepierre,

E. Houvenagel,

C. Nguyen,

. Mh and . Guyot,

N. Segaud, , vol.12

F. Maury,

L. Marguerie,

X. Deprez,

J. H. Salmon,

G. Baudens,

E. Gervais, , vol.17

C. Micelli,

I. Chary-valckenaere, , vol.20

P. Lafforgue, , vol.20

C. Richez,

R. M. Flipo,

T. Pham,

A. University and C. Marseille, , vol.13, p.0

S. A. Rheumatology, . Hospital, and P. Aphp, ) Rheumatology, Henri Mondor Hospital, Rheumatology, Bichat Hospital, issue.6

H. Rheumatology and . Bethune,

, Among the axSpA cohort, evidence of radiographic sacroiliitis, MRI sacroiliitis or elevated CRP were also assessed as potential predictors. Drug survival was analyzed by the Kaplan-Meier method and adjusted for baseline factors were estimated by multiple Cox regression analysis. Results : The main characteristics of the 556 patients (pts) included were the following: 338 (61%) axSpA , 183 (33%) PsA, 324 (58%) female, mean age 47 +/-12 years, 221 (40%) smokers,160 (29%) radiographic sacroiliitis, 238 (43%) MRI sacroiliitis, 206 (37%) elevated CRP, 239 (43%) HLA B27 positive, mean BASDAI 48,9 +/-27%. SEC was associated to methotrexate (MTX) in 140 pts (25%) and was the first line bDMARD in 56 patients (10%). The median drug survival (MDS) of SEC was 76 weeks (w), Private Practice, vol.54, issue.13, pp.65-88, 2016.